| Literature DB >> 31552570 |
Roland Loh1, Emmanuel Stamatakis2, Dirk Folkerts3,4, Judith E Allgrove3, Hannah J Moir5.
Abstract
BACKGROUND: Physical activity (PA) breaks in sitting time might attenuate metabolic markers relevant to the prevention of type 2 diabetes.Entities:
Mesh:
Substances:
Year: 2020 PMID: 31552570 PMCID: PMC6985064 DOI: 10.1007/s40279-019-01183-w
Source DB: PubMed Journal: Sports Med ISSN: 0112-1642 Impact factor: 11.136
Fig. 1Modified PRISMA flow diagram for included and excluded studies
Studies comparing PA breaks with sitting
| Study | Participants | Protocol | Outcomes | Results (please see table footnotes for interpretation of results) |
|---|---|---|---|---|
| Altenburg et al. [ | 5 M 6 W (median, 25%tile–75%tile); age: 21.4 y (19.5–23.1); BMI: 23.2 kg/m2; PA/SB unmentioned | SIT: 1 h baseline + 7 h sitting; INT: sitting (372 min) + 8 min cycling @ 40–60% (52 ± 3.2%) HRR, RPE: 11.2 ± 1.6, hourly (6 × 8) (1st session @ 0 h + 1) | Capillary @ baseline, hourly before exercise: C-peptide, glucose, TAG, HDL-C, LDL-C, TC | C-peptide: INT < SIT; TAG, TC, HDL-C, LDL-C, glucose: ↔ |
| Bailey and Locke [ | 7 M 3 W (mean ± SE); age: 24 ± 3 y; BMI: 26.5 kg/m2 ± 4.3; healthy, PA unmentioned | SIT: sitting 5 h; STAND: sitting (272 min) +2 min standing every 30 min; WALK: sitting (272 min) +2 min walking (3.2 km/h) every 30 min | Capillary: baseline, hourly, before exercise: glucose, BP baseline and 5 h for TAG, HDL-C, TC | Glucose: WALK < STAND and SIT |
| Bailey et al. [ | Healthy 6 M 7 W (mean ± SD); age: 26.6 ± 8 y, < 150 min/w MVPA), not in non-sedentary job; BF: 24.4% ± 8.2% | SIT: sitting 5 h; LIGHT: sitting (272 min) +2 min walking (3.2 km/h) every 30 min; MOD: sitting (272 min) +2 min walking (5.8–7.9 km/h) every 30 min | Cannula: − 1 h, 0 h, hourly, before exercise: subjective appetite, acylated ghrelin, peptide YY, insulin, glucose | a; Glucose iAUC: men < women in CON; in men, glucose iAUC: MOD < LIGHT, MOD < CON |
| Bailey et al. [ | 14 M (mean ± SD); age: 22.1 ± 1.2 y, BMI: 25.0 ± 3.1 kg/m2, BF: 17.2 ± 5.5% | SIT + HIGH GI: high GI breakfast + 4 h sitting; SIT + LOW GI: low GI breakfast + 4 h sitting; INT + HIGH GI: high GI breakfast + 2 min walking/20 min (6.5–8.0 km/h, RPE: 12–14); INT + low GI breakfast: high GI breakfast + 2 min moderate walking/20 min (6.5 to 8.0 km/h, RPE: 12–14) | Capillary for glucose: − 15 min, 15, 30, 45, 60, 90, 120, 180, 240 min for glucose; venous: 60 min 120, 180, 240 min for insulin | a |
| Bhammar et al. [ | 5 M 5 W (mean ± SD); age: M: 31 ± 5 y W: 32 ± 6 y; BMI: M: 30.1 ± 2.3 kg/m2, W: 30.5 ± 6.6 kg/m2; | SIT: 9 h sitting; 2 minMod20: 2min walking at 53 ± 5% HRmax/3 miles/h every 20 min, total 42 min, 240 kcal. 2 minVig60: 2min walking at 79 ± 4% HRmax every hour, total 16 min, 140 kcal; EX: 30 min walking at 71 ± 4% HRmax/56% | CGMS. ABP, MAP | a, Systolic ABP, MAP: EX < SIT |
| Blankenship et al. [ | 2 M 8 W (mean ± SE); age: 51.9 ± 15.4 y; BMI: 31.6 ± 10.0 kg/m2, BF: 42.6 ± 3.3% | EX: 30 min brisk walking, ~ 300 kcal before lunch. FLB: isoenergetic with EX, bouts of sitting ≤ 20 min; FSB: bouts of sitting ≤ 20 min, same number of breaks as FLB but time walking standing reduced to minimise EE | CGMS, catheter for blood, after MMTT at end of day, @ 30, 60, 90, 120 min, for glucose, insulin | Post-prandial glucose and insulin AUC: ↔ between conditions; glycaemic variability: FLB < EX; nocturnal hyperglycaemia: FLB < EX and FSB |
| Brocklebank et al. [ | 8 M 9 W (mean ± SD); age: 52.4 ± 5.1 y; BMI: 28.0 ± 4.5 kg/m2; 8 active, 9 inactive | SIT: 5 h sitting; WALK: 2 min corridor walking @ RPE 9 every 20 min, total 28 min | CGMS | a |
| Champion et al. [ | 12 M 12 W (mean ± SD); age: M: 32.0 ± 10.5 y, W: 39.5 ± 10.3 y; BMI: M: 26.6 ± 4.5 kg/m2, W: 24.8 ± 5.13 kg/m2; sitting time: M: 9.4 ± 2.4 h,W: 9.2 ± 2.4 h | SIT: 6 h 30 min sitting; INT: 20 min walking at 20 min, 80 min, 140 min, 200 min, 260 min, 320 min, self-selected @ 1.2–3.5 km/h, RPE 6–9 | Capillary: 0 h, 45 min, 105 min, 165 min, 225 min, 285 min, 345 min, 390 min; SBP, DBP | a; SBP, DBP: INT < SIT |
| Chen et al. [ | 7 M 4 W (mean ± SD); age: 50 ± 5 y; BMI: 32.5 ± 6.7 kg/m2;bodyfat %: 35 ± 6% | SIT: 315 min sitting; INT, 2 min walking @ 6.4 km/h every 20 min over 315 min, 30 min total | Cannula: 0 h, hourly, and every 15 min after each meal (meal @ 0 h and 180 min), for TAG, glucose, insulin | a |
| Crespo et al. [ | 2 M 7 W (mean ± SD); age: 30 ± 15 y; BMI: 29 ± 3 kg/m2; 2 participants impaired fasting glucose (5.6–6.9 mmol·L−1), 7 prehypertensive (> 120 mmHg SBP or > 80 mmHg DBP; < 150 min/w MVPA | SIT: 8 h sitting, restroom @ 0850 h, between 1000 and 1030 h, lunch (1200–1230 h), and between 1400 and 1500 h, replicated in all conditions; Stand: 2.5 h total standing time, stand 10 min at 0850 and 0950 h, 15 min at 1045 and 1145 h, 20 min at 1240 and 1320 h, and 30 min at 1400 and 1530 h; Walk: walk @ 1mph, same frequency and duration as Stand; Cycle: ~ 20 W, 25–30 RPM, same frequency, duration as Stand | 24 h CGMS, HR, activPAL | 24 h glucose: Stand, Walk, Cycle < Sit, Cycle < Walk < Stand; mean glucose LAB: Cycle < Stand, EVE: Cycle < Stand and Walk, Sleep: Cycle < Sit, Stand, Walk; 6 h postprandial glucose: Cycle, Walk, Stand < Sit; Cycle < Walk < Stand; cumulative 6 h iAUC: Cycle and Walk < Sit, Cycle < Stand |
| Dempsey et al. (2016, 2017) [ | T2D (ADA criteria) 14 M 10 W (mean ± SE); age: 62 ± 6 y, BMI: 33.0 ± 3.4 kg/m2, ≥ 25 < 40 kg/m2;); inactive (sitting ≥ 5 h/d OR < 150 min MVPA/w for 3 months) | SIT: 7 h sitting; WALK: sitting + 3 min walking (3.2 km/h) every 30 min (12 × 3), except during lunch; SRA: sitting + 3 min calisthenics/30 min, 12 × 3 (each 3 min divided into 9 20 s segments, alternating halfsquats, calf raises, gluteal contractions, knee raises); RPE intensity (9 ± 0.3 (7–12) and 10 ± 0.3 (7–13), and HR (mean differences for HR for LW and SRA: 17 ± 1.2 bpm (8–31) and 19 ± 1.0 bpm (10–30) | Cannula: − 1 h, 0 h, then @ 30 min intervals, immediately prior to activity, for glucose, insulin, TAG, c-peptides; CGMS | Glucose: 18 h iAUC: a, greater decrease for women than men for WALK and RA vs SIT; insulin: a; c-peptide: WALK < SIT, SRA < SIT; TAG: SRA < SIT, SRA < WALK; EE: SRA increase of 121 ± 7% vs sitting, LW increase of 73 ± 5% vs sitting; SRA increase of 0.58 ± 0.06 kcal · min−1 vs LW |
| Di Pietro [ | 10 (mean ± SD); age: 69 ± 6 y; BMI: BMI 30 ± 5 kg/m2; impaired fasting glucose | INT: D1: inactive; D2: treadmill walking 3 × 15 min 3 METS postmeals; EXam: D1: inactive; D2: 45 min walking @ 3 METs @ 10.30am; EXpm: D1: inactive; D2: 45 min walking @ 3 METs @ 430 pm | CGMS, glucose; insulin only on sitting days | Glucose: INT: d2 < d1; EXAM: d2 < d1; EXPM: ↔ |
| Dunstan et al. [ | 11 M 8 W (mean ± SD); age: 53.8 y ± 4.9 y; BMI: 31.2 kg/m2 ± 4.1; self-reported sedentary (sitting time > 5 h/d), < 150 min MVPA/w | SIT: sitting 7 h; LIGHT: sitting (402 min) + 2 min walking (3.2 km/h) every 20 min for 5 h; MOD: sitting (402 min) + 2 min MVPA walking (5.8–6.4 km/h) (RPE: 12–14) every 20 min | Catheter: − 2 h, − 1 h, 0 h, then hourly, before activity for glucose, insulin | a |
| Duvivier et al. [ | 2 M 16 W (mean ± SD); age: 21 ± 2 y; BMI: 22.6 ± 3.6 kg/m2; FPG: 4.61 ± 0.31 mmol/L | Over 4 days; SIT: 14 h sitting + 1 h walking + 1 h standing; EX: 13 h sitting + 1 h walking + 1 h standing + 1 h MVPA cycling; INT: 8 h sitting + 5 h walking + 3 h standing | Next day (day 5) fasting glucose, insulin, TAG, HDL-C, non-HDL-C, LDL-C, Apo-A, Apo-B; next day OGTT for IS | Glucose AUC/fasting: ↔; Insulin AUC: INT < SIT, INT < EX; fasting TAG: INT < SIT; fasting non-HDL-C: INT < SIT; Apo B: INT < SIT |
| Duvivier et al. [ | 13 M 6 W; (mean ± SD;)age: 63 ± 9 y, T2D (not on insulin), BMI: 30.5 ± 3.3 kg/m2, self-report MVPA: < 2.5 h/w, FPG: < 11 mmol/L | Over 4 days; SIT: 14 h sitting + 1 h walking + 1 h standing; EX: 13 h sitting + 1 h walking + 1 h standing + 1 h MVPA cycling (3 × 20 min bouts, 5 min rest between bouts); INT: 9 h sitting + 3 h walking + 4 h standing, after every 30 min sitting | Next day (day 5) 24 h CGM glucose; next day glucose, insulin fasting TAG, HDL-C, non-HDL-C, LDL-C, Apo-A, Apo-B | 24 h iAUC GLUC: INT < SIT; Insulin: INT < SIT; HOMA2-IR: INT < SIT and EX; TG: INT and EX < SIT; C-peptide: INT < SIT; NEFA: SIT < INT and EX |
| Duvivier et al. [ | 13 M 11 W (mean ± SD); age: 64 ± 7 y, BMI: 29 ± 2 kg/m2, self-report MVPA: < 2.5 h/w, FPG: < 6.9 mmol/L | Over 4 days; SIT: walking and standing < 1 h/d; SitLess: ≥ 4 h/d of self-perceived light intensity walking, ≥ 3 h/d of standing, interrupt sitting every 30 min with standing/walking bouts | OGTT, catheter: 0 h, 15 min, 30 min, 45 min, 60 min, 90 min, 120 min, 190 min, for glucose, insulin, c-peptide, AG, total cholesterol, HDL-C, LDL-C, non-HDL-C, FFA, APo A-I, Apo B-100 | Glucose AUC/fasting: ↔; insulin AUC/fasting: SitLess < SIT; c-peptide: AUC/fasting: SitLess < SIT; Apo B-100: SitLess < SIT; DBP: SitLess < SIT |
| Engeroff et al. [ | Healthy, 18 W (mean ± SD); age: 25.6 ± 2.6 y, BMI: 21.5 ± 2.0 kg/m2 | SIT: 4 h sitting; EX: 30 min cycling @ 70% VO2 max + 4 h sitting; INT: (40 min sitting + 6 min cycling @ 70% | Venous TAG, TC, HDL-C, LDL-C, baseline, post 240 min | TAG: ↔ between conditions, overall time effect, |
| Hansen et al. [ | 6 M 8 W (mean, 95%CI): age: 22 y (20–23); BMI: 23.0 kg/m2 (21.6–24.4); | SIT: 2.5 h sitting; INT: 2.5 h sitting interrupted with 2 min low intensity walking every 20 min (7 × 2) | Capillary: twice @ baseline, every 10 min for next 2.5 h, for glucose | ↔ |
| Hawari et al. [ | 11 M 3 W (mean ± SD); age: 37 ± 16 y, BMI: 30.5 ± 3.8 kg/m2 | SIT: 390 min sitting; INT: 390 min sitting + 10 chair squats every 20 min over a 3 s period | Cannula: 0 h, 30 min, 60 min, 120 min, 180 min, 210 min, 240 min, 270 min, 330 min, 390 min, for glucose, insulin, TAG | a, Insulin: INT < SIT |
| Henson et al. [ | 22 W (mean ± SD); age: 66.6 ± 4.7 y; BMI: 32.9 ± 4.7 kg/m2; post-menopausal (> 12 m); dysglycaemic IGT (≥ 7.8 mmol/L < 11.1 mmol/L OGTT); sedentary (objectively measured < 150 min/w MVPA) | SIT: D1: 7.5 h sitting, D2: 7.5 h sitting; STAND: 6.5 sitting +5 min standing every 30 min (12 × 5) on D1, + D2 sitting; WALK: 6.5 sitting + 5 min walking, self-selected light intensity (10–12 RPE, < 4 km/h) (12 × 5) + D2 sitting | Cannula: − 1 h, 0 h, post-breakfast and lunch: 30 min, 60 min, 120 min, 180 min, for Glucose, TAG, NEFA | a, Glucose: STAND < SIT; NEFA: WALK > SIT, STAND > SIT |
| Holmstrup et al. [ | Obese, IFG, 8 M 3 W(mean ± SE); age: 25 ± 2.6 y, BMI: 34 kg/m2, Men | SIT: sitting: 12 h; EX: 1 h treadmill running @ 60–65% | Catheter, baseline, every 10 min over 12 h, for glucose, insulin, c-peptides | a; C-peptide: EX < SIT and INT during exercise, 2 h iAUC: EX and INT < SIT |
| Homer et al. [ | 11 M, 25 W (mean ± SD); age: 25 (range: 19–34); BMI: 23.78 ± 4.01 kg/m2, | SIT: D1: 7 h sitting, D2: 5 h sitting; EX: D1: 6 h 30 min sitting + 30 min walking @ 60% | Cannula: D1: 0 h. D2: hourly + 30 min and 45 min post-meal, for TAG, glucose, insulin, NEFA | a; NEFA: ↔ |
| Honda et al. [ | 13 M 3 W (mean ± SE); age: 65.4 ± 1.1 y, BMI: 23.6 ± 0.7 kg/m2, T2D | SIT: 180 min sitting; INT: 180 min sitting + 3 min stair climbing (21 steps × 6 times up and down, 80–110 steps/min) at 60 min and 120 min | Capillary: 0 min, 60, 90, 120, 150, 180 for glucose, C peptide, NEFA, lactate | Glucose: INT < CON; C-peptide: ↔; NEFA: ↔ |
| Kashiwabara et al. [ | 12 W (mean ± SD); age: 70.5 ± 4.6 y; BMI: 25.3 ± 3.5 kg/m2; BP: 144 ± 19 mmHG; DBP: 85 ± 11 mmHG; inactive, < 150 min MVPA/w | SIT: 8 h sitting; INT: sitting + 1.5 min walking every 15 min @ 3.6 km/h, RPE: 11 @ 1 h, 1 h 15 min, 1 h 30 min, 1 h 45 min, 2 h 15 min, 2 h 30 min, 2 h 45 min, 4 h 15 min, 4 h 30 min, 4 h 45 min, 5 h, 5 h 15 min, 5 h 30 min, 5 h 45 min, 6 h 15 min, 6 h 30 min, 6 h 45 min, 7 h, 7 h 15 min, 7 h 30 min | Venepuncture: 0 h, 2 h, 4 h, 6 h, 8 h, for glucose, insulin, TAG, NEFA, APoB-48, ApoB-100, LPL | a; Apo B-48, Apo B-100, LPL: ↔ |
| Kerr et al. [ | 9 W (mean ± SD); age: 66 ± 9 y; BMI: 30.6 ± 4.2 kg/m2; SBP: 123 ± 8 mmHG; DBP: 66 ± 7 mmHG | SIT: 5 h sitting; INT: 2 min walking every hour | Cannula: − 0.5 h, 0 h, every 30 min, for glucose, insulin; HR, BP, − 1 h, 0 h, every 30 min | a, SBP, DBP, HR: ↔ |
| Kim et al. [ | 9 M (mean ± SD); age: 24.0 ± 4.0 y; | SIT: D1 and D2: (7000–7500 steps/day, D3: 9 h sitting (< 2000 steps, 0900–1800), D4: HFTT; MOD: D1, D2, D4: same as SIT, D3: sitting +1 h running @ 65% | D4 fasting and postprandial FFA, TAG, glucose, insulin, indirect calorimetry for postprandial substrate oxidisation | a; FFA: MOD > INT and SIT |
| Larsen et al. [ | 11 M 8 W (mean ± SE); age: 56.7 ± 1.5 y; BMI: 32.7 ± 1 kg/m2; Sedentary (sitting > 5 h/day, self-report, < 150 min/w MVPA) | SIT: 7 h sitting; INT: sitting (402 min) + 2 min walking (3.2 km/h) every 20 min for 5 h, 3 day protocol: on D1 and D3, SIT vs INT | Cannula: − 1 h, 0 h, hourly, before exercise for glucose, insulin, TAG; model of insulin sensitivity | a |
| Maylor et al. [ | 7 M 7 W (mean ± SD); age: 29 ± 9 y, BMI: 26.1 ± 5.8 kg/m2, | SIT: 8H sitting; EX: 30 min sitting + 30 min treadmill running @ 60% VO2 reserve + 7 h sitting; INT: 30 min sitting + 2 min 32 s running @ 85% | Cannula: 0 h. hourly intervals, for TAG, glucose, insulin, HDL-C | a; HDL-C: INT < SIT |
| McCarthy et al. [ | 6 M 7 W (mean ± SD); age: 66 ± 6 y; BMI: 33.8 ± 3.8;SBP: 140 ± 13 mmHG; DBP: 79 ± 9 mmHG; < 150 min MVPA/w | SIT: 7.5 h sitting; INT: 7.5 sitting + 5 min arm ergometry @ intensity similar to 3 km/h walking, total 1 h (12 ×) | Cannula: 0 h, 30 min, 60 min, 120 min, 180 min, for glucose, insulin | a |
| McCarthy et al. [ | 16 M 18 W (median ± IQR); age: M: 35 ± 17, W: 43 ± 13; BMI: M: 25.9 ± 5.1, W: 22.7 ± 4.6; | SIT: 7.5 h sitting; INT: 6.5 h sitting +5 min walking @ 3 km/h every 30 min, total 1 h | Cannula: − 1 h, 0 h, 30 min, 1 h, 2 h, 3 h, 210 min, 4 h, 5 h, 6 h, 390 min, for glucose, insulin | a |
| Miyashita et al. [ | 10 M (mean ± SE); age: 25.0 ± 1.3 y, BMI: 25.4 ± 1.2 kg/m2, WC: 87.2 ± 3.5 cm, BF: 9.4 ± 0.7% | 1.SIT: D1: 7 h sitting, D2: 7 h sitting; 2. EX: D1: 6 h 30 min sitting + 30 min running @ 71.1 ± 2.3% | D2 cannula: 0 h, hourly intervals, and @ 0.5, 0.75, 3.5, 3.75 h fasting and post-prandial for TAG, glucose, insulin, NEFA, 3-OHB; | a; NEFA, 3-OHB: ↔ |
| Miyashita et al. [ | 19 M (M ± SE); age: 22.7 ± 0.5 y, BMI: 23.8 ± 0.8 kg/m2; | SIT: D1: sitting, 830/900 to 1600/1700, D2: 7 h sitting; INT: day1: sitting similar to SIT + 6 min running @ 70% | D2 venous: hourly, and at 0.5 h, 0.75 h, 3.5 h, 3.75 h, for glucose, insulin, TAG, NEFA | a NEFA: INT > SIT |
| Miyashita et al. [ | 15 M; (mean ± SE): age: 23.4 ± 0.8 y, | 1. SIT: D1: 7 h sitting, D2: 7 h sitting; 2: day1: EX: 30 min walking @ 6.8 km/h ± 0.1 (42.4 ± 1.8% | Next day TAG, glucose, insulin; BP: day1: baseline, every 5 and 15 min post-exercise in INT, and at corresponding time points in EX and SIT, day2: baseline, hourly | a; SBP: INT > SIT and EX during intermittent walking, lower 15 min post each walking, D2: INT and EX < SIT |
| Miyashita [ | 8 M (mean ± SE); age: 26.5 ± 1.5 y; BMI: 28.9 ± 1.4 kg/m2; SBP: 131 ± 4 DBP: 82 ± 5 mmHg | SIT: D1: 7 h sitting, day2: 6 h sitting; EX: day1: 30 min cycling @ 60% max HR after 30 min sitting, D2: 6 h sitting; 3. INT: day1: 10 × 3 min cycling @ 60% max HR, day2: 6 h sitting | Venepuncture on D2: 0 h, 2 h, 4 h, 6 h for TG, NEFA, 3OHB, insulin, plasma glucose | a Postprandial: TAG (tAUC): EX and INT < SIT; INT and EX tending < SIT, main effect for 3OHB, exercise trials trending higher |
| Miyashita et al. [ | 10 M (mean ± SE); age: 24.4 ± 1.4 y, height: 176.8 ± 1.8 cm, weight: 71.2 ± 2.1 kg, BMI: 22.8 ± 0.6 kg/m2, WC: 78.0 ± 1.1 cm, bodyfat: 8.8% ± 0.7%, | SIT: sitting 9 h; INT: 9 h sitting + 6 × 5 min running @ 70% | Cannula: 0 h, 1 h 30 min, 3 h, 4 h 30 min, 6 h, 7 h 30 min, 9 h for plasma TAG, glucose, insulin; serum CRP at 0 h, 9 h | a CRP: ↔ |
| Miyashita et al. [ | Inactive, 15 W (mean ± SD); age: 68.8 ± 3.2 y, BMI: 24.0 ± 2.9 kg/m2 SBP: 135 ± 19 mm Hg DBP: 85 ± 10 mm Hg | 1. SIT: 8 h sitting; 2. EX: 1 h sitting- > 30 min walking @ 3.7 ± 1.1 km/h, RPE: 12 ± 1 (0.33 ± 0.07 MJ/30 min)- > 6 h 30 min sitting 3. INT: 1 h sitting- > 20 × 1.5 min walking every 15 min @ 3.7 ± 1.1 km/h RPE: 11 ± 1 | Venous: 0 h, 2 h, 4 h, 6 h, 8 h for TAG, NEFA, 3-OHB, insulin, glucose | a, NEFA: ↔; 3-OHB: INT > SIT, EX |
| Peddie et al. [ | 28 M 42 W (mean ± SD); age: (25.9 ± 5.3 y) BMI: 23.6 ± 4.0 kg/m2, questionnaire < 2.5 h/w (90 ± 42 min)PA; Healthy | 1. SIT: 9 h sitting; 2. EX: 15 min sitting + 30 min treadmill walking @60% | Cannula, 16 total: baseline, hourly, and 6 additional 30 and 45 min after meals for glucose, insulin, TAG | a |
| Pulsford et al. [ | 25 M (mean ± SD); age: 40.2 ± 12.2 y; inactive; BMI: 26.1 ± 4.1 kg/m2; BF: 26.6 ± 6% | SIT: 7 h sitting; STAND: sitting + 2 min standing every 20 min; WALK: sitting + 2 min walking (2mph) every 20 min | Cannula: − 1.5 h, OGTT @ 0 h, every 10 min for 30 min, then mixed meal @ 3 h, every 10 min for 30 min, every 30 min until 7 h for glucose, insulin, Matsuda index | a Matsuda: WALK < SIT |
| Rodriguez-Hernandez et al. [ | 10 W (mean ± SE); age: 36 ± 5 y; BMI: 38.0 ± 5.66 kg/m2; bodyfat %: 49.57 ± 1.38% | SIT: 4 h sitting: WALK2 min: 2 min walking every 30 min, total 16 min, between 4 h sitting; WALK5 min: 5 min walking every 30 min, total 40 min, between 4 h sitting | 4 h CGMS for glucose | a |
| Van Dijk et al. [ | T2D patients (ADA criteria) 20 M (mean ± SD); age: 64 ± 1 y; BMI: 29.5 ± 0.9 kg/m2, PA unreported | SIT: 11 h? sitting; EX: sitting + breakfast + 45 min cycling @ 50% max workload capacity (EE: 350 kcal) + sitting; INT: sitting + 3 × 15 bouts of walking after each 3 meals (EE: 175 kcal) | Glucose CGMS; total 9 venous: 5 min before each meal, 90, 150 after each meal, last sample @ 1930 for glucose, insulin | Hyperglycaemia: EX < INT and SIT; a |
| Vincent et al. [ | 6 M (mean ± SD); age: 27.0 ± 3.7 y; BMI: 24.8 ± 2.0 kg/m2 | SIT: sleep restricted: D1, D2, D3: 700–200; INT: sleep restricted: D1, D2, D3: sitting 700–200, from 1000–1700, 3 min walking @ 3.2 km/h every 30 min, 51 min total walking | CGMS | |
| Wennberg et al. [ | 10 M 9 W (mean ± SD); age: 45–75 y, BMI: 31.5 ± 4.7 kg/m2; sitting time: 9.82 ± 2.19 h, MVPA ≤ 150 min/week | SIT: sitting 7 h; INT: sitting (402 min) + 3 min walking (3.2 km/h) every 30 min for 5 h, total 10 | CGMS for glucose, cannula for insulin, BDNF, IL6, cortisol | a ↔ |
aSee Figs. 2, 4, 7
↔ no statistically significant difference between measures, ↑ increase; < statistically significantly less than, e.g. if Glucose: Walk < Stand and Sit, this means AUC for glucose for the WALK condition was less than the STAND condition, and also less than the SIT condition, @ at, D1 day 1, D2 day2, mean ± SD mean ± standard deviation, mean ± SE mean ± standard error, mean ± IQR mean ± interquartile range, RPE rating of perceived exertion, MET metabolic equivalents, CGMS continuous glucose monitoring system, T2D type 2 diabetes, OGTT oral glucose tolerance test, HFTT high fat tolerance test, FPG fasting plasma glucose, CVD cardiovascular disease, IFG impaired fasting glucose, GI Glycaemic Index, CRP c reactive protein, LPL lipoprotein lipase, NEFA Non-esterified fatty acids, HDL-C high density lipoprotein cholesterol, LDL-C low density lipoprotein cholesterol, TC total cholesterol, Apo A-I apoliprotein A-I, Apo B-48 apoliprotein B-48, Apo B-100 apolipoprotein B-100, SBP systolic blood pressure, DBP dystolic blood pressure, ABP ambulatory blood pressure, HR heart rate, 3OHB beta-hydroxy-butyrate, BDNF brain-derived neurotrophic factor, IL6 interleukin 6, HbA1c haemoglobin A1c, M men, W women, y years old, min minute
Fig. 2Forest plot for the effects of physical activity (PA) breaks on TAG measures, multi-day vs 1 day; D1: Day 1, d2: day 2
Fig. 3Forest plot for the effects of physical activity (PA) breaks on TAG measures. D1: day 1, D2: day2
Fig. 4Forest plot for the effects of physical activity (PA) breaks on glucose measures; GI: glycaemic index
Fig. 5Forest plot for the effects of physical activity (PA) breaks on glucose measures, active vs inactive/unfit/T2D/IFG/overweight/obese; T2D; type 2 diabetes, IFG: impaired fasting glucose, GI: glycaemic index
Fig. 6Forest plot for the effects of physical activity (PA) breaks vs continuous exercise on glucose measures, stratified by sex; GI: glycaemic index
Fig. 7Forest plot for the effects of physical activity (PA) breaks on insulin measures; GI: glycaemic index
Fig. 8Forest plot for the effects of physical activity (PA) breaks on glucose measures, active vs inactive/unfit/T2D/IFG/overweight/obese; T2D; type 2 diabetes, IFG: impaired fasting glucose, GI: glycaemic index
Studies comparing PA breaks with 1 bout of continuous/prolonged exercise
| Study | Participants | Protocol | Outcomes | Results |
|---|---|---|---|---|
| Bhammar et al. [ | 5 M 5 W (mean ± SD); age: M: 31 ± 5 y W: 32 ± 6 y; BMI: M: 30.1 ± 2.3 kg/m2, W: 30.5 ± 6.6 kg/m2; | SIT: 9 h sitting; 2 minMod20: 2min walking at 53 ± 5% HR max/3 miles/h every 20 min, total 42 min, 240 kcal. 2 minVig60: 2min walking at 79 ± 4% HR max every hour, total 16 min, 140 kcal; EX: 30 min walking at 71 ± 4% HRmax/56% | CGMS. ABP, MAP | a, Systolic ABP, MAP: EX < SIT |
| Blankenship et al. [ | 2 M 8 W (mean ± SE); age: 51.9 ± 15.4 y; BMI: 31.6 ± 10.0 kg/m2, BF: 42.6 ± 3.3% | EX: 30 min brisk walking, ~ 300 kcal before lunch. FLB: isoenergetic with EX, bouts of sitting ≤ 20 min; FSB: bouts of sitting ≤ 20 min, same number of breaks as FLB but time walking standing reduced to minimise EE | CGMS, catheter for blood, after MMTT at end of day, @ 30, 60, 90, 120 min, for glucose, insulin | Post-prandial glucose and insulin AUC: ↔ between conditions; glycaemic variability: FLB < EX; nocturnal hyperglycaemia: FLB < EX and FSB |
| Di Pietro [ | 10 (mean ± SD); age: 69 ± 6 y; BMI: BMI 30 ± 5 kg/m2; impaired fasting glucose | INT: D1: inactive; D2: treadmill walking 3 × 15 min 3 METS postmeals; EXam: D1: inactive; D2: 45 min walking @ 3 METs @ 10.30 am; EXpm: D1: inactive; D2: 45 min walking @ 3 METs @ 430 pm | CGMS, glucose; insulin only on sitting days | Glucose: INT: d2 < d1; EXAM: d2 < d1; EXPM: ↔ |
| Duvivier et al. [ | 2 M 16 W (mean ± SD); age: 21 ± 2 y; BMI: 22.6 ± 3.6 kg/m2; FPG: 4.61 ± 0.31 mmol/L | Over 4 days; SIT: 14 h sitting + 1 h walking + 1 h standing; EX: 13 h sitting + 1 h walking + 1 h standing + 1 h MVPA cycling; INT: 8 h sitting + 5 h walking + 3 h standing | Next day (day 5) fasting glucose, insulin, TAG, HDL-C, non-HDL-C, LDL-C, Apo-A, Apo-B; next day OGTT for IS | Glucose AUC/fasting: ↔; Insulin AUC: INT < SIT, INT < EX; fasting TAG: INT < SIT; fasting non-HDL-C: INT < SIT; Apo B: INT < SIT |
| Duvivier et al. [ | 13 M 6 W; (mean ± SD;)age: 63 ± 9 y, T2D (not on insulin), BMI: 30.5 ± 3.3 kg/m2, self-report MVPA: < 2.5 h/w, FPG: < 11 mmol/L | Over 4 days; SIT: 14 h sitting + 1 h walking + 1 h standing; EX: 13 h sitting + 1 h walking + 1 h standing + 1 h MVPA cycling (3 × 20 min bouts, 5 min rest between bouts); INT: 9 h sitting + 3 h walking + 4 h standing, after every 30 min sitting | Next day (day 5) 24 h CGM glucose; next day glucose, insulin fasting TAG, HDL-C, non-HDL-C, LDL-C, Apo-A, Apo-B | 24 h iAUC GLUC: INT < SIT; Insulin: INT < SIT; HOMA2-IR: INT < SIT and EX; TG: INT and EX < SIT; C-peptide: INT < SIT; NEFA: SIT < INT and EX |
| Engeroff et al. [ | Healthy, 18 W (mean ± SD); age: 25.6 ± 2.6 y, BMI: 21.5 ± 2.0 kg/m2 | SIT: 4 h sitting; EX: 30 min cycling @ 70% VO2 max + 4 h sitting; INT: (40 min sitting + 6 min cycling @ 70% | Venous TAG, TC, HDL-C, LDL-C, baseline, post 240 min | TAG: ↔ between conditions, overall time effect, |
| Holmstrup et al. [ | Obese, IFG, 8 M 3 W(mean ± SE); age: 25 ± 2.6 y, BMI: 34 kg/m2, Men | SIT: sitting: 12 h; EX: 1 h treadmill running @ 60–65% | Catheter, baseline, every 10 min over 12 h, for glucose, insulin, c-peptides | a; C-peptide: EX < SIT and INT during exercise, 2 h iAUC: EX and INT < SIT |
| Homer et al. [ | 11 M, 25 W (mean ± SD); age: 25 (19–34); BMI: 23.78 ± 4.01 kg/m2, | SIT: D1: 7 h sitting, D2: 5 h sitting; EX: D1: 6 h 30 min sitting + 30 min walking @ 60% | Cannula: D1: 0 h. D2: hourly + 30 min and 45 min post-meal, for TAG, glucose, insulin, NEFA | a; NEFA: ↔ |
| Kashiwabara et al. [ | 12 W (mean ± SD); age: 70.5 ± 4.6 y; BMI: 25.3 ± 3.5 kg/m2; BP: 144 ± 19 mmHG; DBP: 85 ± 11 mmHG; inactive, < 150 min MVPA/w | SIT: 8 h sitting; INT: sitting + 1.5 min walking every 15 min @ 3.6 km/h, RPE: 11 @ 1 h, 1 h 15 min, 1 h 30 min, 1 h 45 min, 2 h 15 min, 2 h 30 min, 2 h 45 min, 4 h 15 min, 4 h 30 min, 4 h 45 min, 5 h, 5 h 15 min, 5 h 30 min, 5 h 45 min, 6 h 15 min, 6 h 30 min, 6 h 45 min, 7 h, 7 h 15 min, 7 h 30 min | Venepuncture: 0 h, 2 h, 4 h, 6 h, 8 h, for glucose, insulin, TAG, NEFA, APoB-48, ApoB-100, LPL | a; Apo B-48, Apo B-100, LPL: ↔ |
| Kim et al. [ | 9 M (mean ± SD); age: 24.0 ± 4.0 y; | SIT: D1 and D2: (7000–7500 steps/day, D3: 9 h sitting (< 2000 steps, 0900–1800), D4: HFTT; MOD: D1, D2, D4: same as SIT, D3: sitting +1 h running @ 65% | D4 fasting and postprandial FFA, TAG, glucose, insulin, indirect calorimetry for postprandial substrate oxidisation | a; FFA: MOD > INT and SIT |
| Maylor et al. [ | 7 M and7 W (mean ± SD); age: 29 ± 9 y, BMI: 26.1 ± 5.8 kg/m2, | SIT: 8H sitting; EX: 30 min sitting + 30 min treadmill running @ 60% VO2 reserve + 7 h sitting; INT: 30 min sitting + 2 min 32 s running @ 85% VO2 reserve every 60 min, 8 bouts | Cannula: 0 h. hourly intervals, for TAG, glucose, insulin, HDL-C | a; HDL-C: INT < SIT |
| Miyashita et al. [ | 10 M (mean ± SE); age: 25.0 ± 1.3 y, BMI: 25.4 ± 1.2 kg/m2, WC: 87.2 ± 3.5 cm, BF: 9.4 ± 0.7% | 1.SIT: D1: 7 h sitting, D2: 7 h sitting; 2. EX: D1: 6 h 30 min sitting + 30 min running @ 71.1 ± 2.3% | D2 cannula: 0 h, hourly intervals, and @ 0.5, 0.75, 3.5, 3.75 h fasting and post-prandial for TAG, glucose, insulin, NEFA, 3-OHB | a; NEFA, 3-OHB: ↔ |
| Miyashita et al. [ | 15 M; (mean ± SE): age: 23.4 ± 0.8 y, | 1. SIT: D1: 7 h sitting, D2: 7 h sitting; 2: day1: EX: 30 min walking @ 6.8 km/h ± 0.1 (42.4 ± 1.8% | Next day TAG, glucose, insulin; BP: day1: baseline, every 5 and 15 min post-exercise in INT, and at corresponding time points in EX and SIT, day2: baseline, hourly | a; SBP: INT > SIT and EX during intermittent walking, lower 15 min post each walking, D2: INT and EX < SIT |
| Miyashita et al. [ | Inactive, 15 W (mean ± SD); age: 68.8 ± 3.2 y, BMI: 24.0 ± 2.9 kg/m2 SBP: 135 ± 19 mm Hg DBP: 85 ± 10 mm Hg | 1. SIT: 8 h sitting; 2. EX: 1 h sitting- > 30 min walking @ 3.7 ± 1.1 km/h RPE RPE 12 ± 1 (0.33 ± 0.07 MJ/30 min)- > 6 h 30 min sitting 3. INT: 1 h sitting- > 20 × 1.5 min walking every 15 min @ 3.7 ± 1.1 km/h RPE: 11 ± 1 | Venous: 0 h, 2 h, 4 h, 6 h, 8 h for TAG, NEFA, 3-OHB, insulin, glucose | a, NEFA: ↔; 3-OHB: INT > SIT, EX |
| Peddie et al. [ | 28 M 42 W (mean ± SD); age: (25.9 ± 5.3 y) BMI: 23.6 ± 4.0 kg/m2, questionnaire < 2.5 h/w (90 ± 42 min)PA; Healthy | 1. SIT: 9 h sitting; 2. EX: 15 min sitting + 30 min treadmill walking @60% | Cannula, 16 total: baseline, hourly, and 6 additional 30 and 45 min after meals for glucose, insulin, TAG | a |
| Van Dijk et al. [ | T2D patients (ADA criteria) 20 M (mean ± SD); age: 64 ± 1 y; BMI: 29.5 ± 0.9 kg/m2, PA unreported | SIT: 11 h? sitting; EX: sitting + breakfast + 45 min cycling @ 50% max workload capacity (EE: 350 kcal) + sitting; INT: sitting + 3 × 15 bouts of walking after each 3 meals (EE: 175 kcal) | Glucose CGMS; total 9 venous: 5 min before each meal, 90, 150 after each meal, last sample @ 1930 for glucose, insulin | Hyperglycaemia: EX < INT and SIT;a |
aSee Figs. 9, 10, 12
↔ no statistically significant difference between measures, ↑ increase; < statistically significantly less than, e.g. if Glucose: Walk < Stand and Sit, this means AUC for glucose for the WALK condition was less than the STAND condition, and also less than the SIT condition, @ at, D1 day 1, D2 day2, mean ± SD mean ± standard deviation, mean ± SE mean ± standard error, mean ± IQR mean ± interquartile range, RPE rating of perceived exertion, MET metabolic equivalents, CGMS continuous glucose monitoring system, T2D type 2 diabetes, OGTT oral glucose tolerance test, HFTT high fat tolerance test, FPG fasting plasma glucose, CVD cardiovascular disease, IFG impaired fasting glucose, GI Glycaemic Index, CRP c reactive protein, LPL lipoprotein lipase, NEFA non-esterified fatty acids, HDL-C high density lipoprotein cholesterol, LDL-C low density lipoprotein cholesterol, TC total cholesterol, Apo A-I apoliprotein A-I, Apo B-48 apoliprotein B-48, Apo B-100 apolipoprotein B-100, SBP systolic blood pressure, DBP dystolic blood pressure, ABP ambulatory blood pressure, HR heart rate, 3OHB beta-hydroxy-butyrate, BDNF brain-derived neurotrophic factor, IL6 interleukin 6, HbA1c haemoglobin A1c, M men, W women, y years old, min minute
Fig. 9Forest plot for the effects of physical activity (PA) breaks vs continuous exercise on TAG measures, multi-day vs 1 day; D1: Day 1, d2: day 2
Fig. 10Forest plot for the effects of physical activity (PA) breaks vs continuous exercise on glucose measures
Fig. 11Forest plot for the effects of physical activity (PA) breaks on glucose measures, stratified by sex
Fig. 12Forest plot for the effects of physical activity (PA) breaks vs continuous exercise on insulin measures
Fig. 13Bubble plot illustrating the association between BMI and SMD when PA breaks were compared with sitting on blood glucose measures. A bubble represents a study. A negative value for SMD means that PA breaks resulted in lower blood glucose values, a positive SMD indicates that sitting resulted in lower glucose values
Fig. 14Bubble plot illustrating the association between BMI and SMD when PA breaks were compared with sitting on blood glucose measures. A bubble represents a study. A negative value for SMD means that PA breaks resulted in lower blood glucose values, a positive SMD indicates that sitting resulted in lower glucose values
Fig. 15Funnel plot for triacylglycerol measures, random-effects model: physical activity breaks versus sitting. A filled circle represents a study; an empty circle, if present, represents a “missing” study by the trim and fill method
Fig. 16Funnel plot for glucose measures, random-effects model: physical activity breaks versus sitting. A filled circle represents a study; an empty circle, if present, represents a “missing” study by the trim and fill method
Fig. 17Funnel plot for insulin measures, random-effects model: physical activity breaks versus sitting. A filled circle represents a study; an empty circle, if present, represents a “missing” study by the trim and fill method
Statistical tests for publication bias for the meta-analyses of glucose, insulin, and TAG levels: physical activity breaks vs sitting, physical activity breaks vs continuous exercise
| Metabolic variable | Rosenthal’s fail-safe | Begg and Mazumdar ( | Egger ( | SMD, assuming severe 2-tailed selection bias |
|---|---|---|---|---|
| Glucose, breaks vs sitting | 1358 | 0.09 | − 1.25, 0.22 | − 0.41 |
| Insulin, breaks vs sitting | 907 | 0.03 | − 0.80, 0.43 | − 0.43 |
| TAG, breaks vs sitting | 87 | 0.005 | − 2.09, 0.05 | − 0.20 |
SMD standardised mean difference
Statistical tests for publication bias for the meta-analyses of glucose, insulin, and TAG levels, physical activity breaks vs sitting
| Metabolic variable | Rosenthal’s fail-safe | Begg and Mazumdar ( | Egger ( | SMD, assuming severe 2-tailed selection bias |
|---|---|---|---|---|
| Glucose, breaks vs continuous | 12 | 0.27 | 1.61, 0.13 | − 0.17 |
| Insulin, breaks vs continuous | 0 | 0.00009 | 1.06, 0.32 | 0.14 |
| TAG, breaks vs continuous | 0 | 1.0000 | − 1.35, 0.21 | 0.02 |
SMD standardized mean difference
Risk of bias summary for included studies
| Study | Random sequence generation (selection bias) | Allocation concealment (selection bias) | Blinding of participants and personnel (performance bias) | Blinding of outcome assessment (detection bias) | Incomplete outcome data (attrition bias) | Selective reporting (reporting bias) | Other bias |
|---|---|---|---|---|---|---|---|
| Bailey et al. [ | ? | ? | N | N | Y | Y | Y |
| Bailey et al. [ | ? | ? | N | N | Y | Y | Y |
| Bailey et al. [ | ? | ? | N | N | Y | Y | Y |
| Bailey et al. [ | ? | ? | N | N | Y | Y | Y |
| Bhammar et al. [ | ? | ? | N | N | Y | Y | Y |
| Blakenship et al. [ | ? | ? | N | N | Y | Y | Y |
| Brocklebank et al. [ | Y | Y | N | N | Y | Y | Y |
| Champion et al. [ | ? | ? | N | N | Y | Y | Y |
| Chen et al. [ | ? | ? | N | N | Y | Y | Y |
| Crespo et al. [ | ? | ? | N | N | Y | Y | Y |
| Dempsey et al. [ | Y | Y | ? | Y | Y | Y | Y |
| Di Pietro et al. [ | ? | ? | N | N | Y | Y | Y |
| Dunstan et al. [ | Y | Y | ? | Y | Y | Y | Y |
| Duvivier et al. [ | ? | ? | N | N | Y | Y | Y |
| Duvivier et al. [ | Y | Y | N | Y | Y | Y | Y |
| Duvivier et al. [ | Y | Y | N | Y | Y | Y | Y |
| Engeroff et al. [ | N | N | N | N | Y | N | Y |
| Hansen et al. [ | ? | ? | N | N | Y | Y | Y |
| Hawari et al. [ | ? | ? | N | N | Y | Y | Y |
| Henson et al. [ | ? | ? | ? | Y | Y | Y | Y |
| Holmstrup et al. [ | ? | ? | N | N | Y | N | ? |
| Homer et al. [ | ? | ? | N | N | Y | Y | Y |
| Honda et al. [ | ? | ? | N | N | Y | Y | Y |
| Kashiwabara et al. [ | ? | ? | N | N | Y | Y | Y |
| Kerr et al. [ | ? | ? | N | N | Y | Y | Y |
| Kim et al. | ? | ? | N | N | Y | N | Y |
| Larsen et al. [ | Y | Y | ? | N | Y | N | Y |
| Maylor et al. [ | ? | ? | N | N | Y | Y | Y |
| McCarthy et al. [ | ? | ? | N | N | Y | Y | Y |
| McCarthy et al. [ | ? | ? | N | N | Y | Y | Y |
| Miyashita et al. [ | ? | ? | N | N | Y | N | Y |
| Miyashita et al. [ | ? | ? | N | N | Y | Y | Y |
| Miyashita et al. [ | ? | ? | N | N | Y | N | Y |
| Miyashita et al. [ | ? | ? | N | N | Y | N | Y |
| Miyashita et al. [ | ? | ? | N | N | ? | ? | Y |
| Miyashita et al. [ | ? | ? | N | N | Y | Y | Y |
| Peddie et al. [ | Y | Y | N | N | Y | N | Y |
| Pulsford et al. [ | Y | Y | ? | N | Y | N | Y |
| Rodriguez-Hernandez et al. [ | ? | ? | N | N | Y | N | Y |
| Van Dijk et al. [ | ? | ? | N | N | Y | N | Y |
| Vincent et al. [ | ? | ? | N | N | Y | N | Y |
| Wennberg et al. [ | Y | Y | N | N | Y | N | Y |
Y not at risk of bias for this condition, N at risk of bias for this condition, ? risk of bias for this condition is unknown based on the reported methodology
| Breaking up sitting with physical activity (PA) moderately attenuated post-prandial glucose and insulin, with a small effect size attenuation for TAG. |
| There was greater glycaemic attenuation in people with higher body mass index (BMI). |
| PA breaks were slightly more effective for glycaemic attenuation compared to one continuous bout of PA when experimental conditions were energy expenditure matched. |